E256 - Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.
Published: June 2, 2025
Duration: 55:50
We love to hear from our listeners. Send us a message.
On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug development efforts at atai are focused on short-duration psychedelics that can work within existing healthcare infrastructure, with the potential to transform the treatment of mental health disorders. Rao also talks about atai's hub and spoke model for investing in other psychedelic companies, what MAPS/Lykos Therapeutics got wrong...